Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Cadila Seeks To Cut The Pain Of GLP-1 Injectables As It Goes For Safety Studies Of Novel Oral Compound

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - It may be early days but researchers at the sprawling Zydus Research Center located near the Western Indian city of Ahmedabad are upbeat about their latest finding - a novel orally administered GLP-1 agonist named ZYOG1- now ready to be tested on humans

You may also be interested in...



Novo Nordisk Expects Strong Patient Benefits To Propel Victoza Sales In India But Will Pricing Get In The Way?

MUMBAI - Enthused by better-then-expected performance of its latest GLP-1 agonist Victoza (liraglutide) in the U.S., Novo Nordisk hopes that its new offering will find wide acceptance among Indian diabetologists and endocrinologists as it gears up for a nationwide launch. In addition to the U.S., Canada, India and E.U., Victoza has been introduced in a short span of time in 11 countries and will soon be available in Japan

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel